• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $LXEO

    Lexeo Therapeutics Inc.

    Subscribe to $LXEO
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    IPO Year: 2023

    Exchange: NASDAQ

    Recent Analyst Ratings for Lexeo Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    7/31/2025$20.00Outperform
    Oppenheimer
    6/13/2024$28.00Outperform
    Robert W. Baird
    6/6/2024$22.00Buy
    H.C. Wainwright
    11/28/2023$20.00Overweight
    JP Morgan
    11/28/2023$20.00Buy
    Stifel
    11/28/2023$19.00Outperform
    Leerink Partners
    11/28/2023$22.00Outperform
    RBC Capital Mkts
    11/28/2023$23.00Buy
    Chardan Capital Markets
    See more ratings

    Lexeo Therapeutics Inc. SEC Filings

    View All

    Lexeo Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Lexeo Therapeutics, Inc. (0001907108) (Filer)

    10/7/25 6:03:59 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Lexeo Therapeutics Inc.

    SCHEDULE 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)

    8/14/25 4:58:22 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Lexeo Therapeutics Inc.

    SCHEDULE 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)

    8/14/25 1:40:44 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Lexeo Therapeutics Inc.

    SCHEDULE 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)

    8/14/25 11:46:25 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Lexeo Therapeutics Inc.

    10-Q - Lexeo Therapeutics, Inc. (0001907108) (Filer)

    8/14/25 7:33:33 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lexeo Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits

    8-K - Lexeo Therapeutics, Inc. (0001907108) (Filer)

    8/14/25 7:31:49 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SCHEDULE 13G filed by Lexeo Therapeutics Inc.

    SCHEDULE 13G - Lexeo Therapeutics, Inc. (0001907108) (Subject)

    8/14/25 6:40:39 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Lexeo Therapeutics Inc.

    SCHEDULE 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)

    8/7/25 4:18:58 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B3 filed by Lexeo Therapeutics Inc.

    424B3 - Lexeo Therapeutics, Inc. (0001907108) (Filer)

    7/1/25 8:09:31 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed by Lexeo Therapeutics Inc.

    EFFECT - Lexeo Therapeutics, Inc. (0001907108) (Filer)

    7/1/25 12:15:35 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lexeo Therapeutics Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Cholmondeley Paula H bought $104,852 worth of shares (15,000 units at $6.99), increasing direct ownership by 96% to 30,627 units (SEC Form 4)

    4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

    11/26/24 5:00:06 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lexeo Therapeutics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer initiated coverage on Lexeo Therapeutics with a new price target

    Oppenheimer initiated coverage of Lexeo Therapeutics with a rating of Outperform and set a new price target of $20.00

    7/31/25 7:37:07 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Robert W. Baird initiated coverage on Lexeo Therapeutics with a new price target

    Robert W. Baird initiated coverage of Lexeo Therapeutics with a rating of Outperform and set a new price target of $28.00

    6/13/24 7:10:25 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright initiated coverage on Lexeo Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Lexeo Therapeutics with a rating of Buy and set a new price target of $22.00

    6/6/24 7:17:54 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    JP Morgan initiated coverage on Lexeo Therapeutics with a new price target

    JP Morgan initiated coverage of Lexeo Therapeutics with a rating of Overweight and set a new price target of $20.00

    11/28/23 7:29:52 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Stifel initiated coverage on Lexeo Therapeutics with a new price target

    Stifel initiated coverage of Lexeo Therapeutics with a rating of Buy and set a new price target of $20.00

    11/28/23 7:29:32 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    RBC Capital Mkts initiated coverage on Lexeo Therapeutics with a new price target

    RBC Capital Mkts initiated coverage of Lexeo Therapeutics with a rating of Outperform and set a new price target of $22.00

    11/28/23 7:29:00 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Leerink Partners initiated coverage on Lexeo Therapeutics with a new price target

    Leerink Partners initiated coverage of Lexeo Therapeutics with a rating of Outperform and set a new price target of $19.00

    11/28/23 7:29:00 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chardan Capital Markets initiated coverage on Lexeo Therapeutics with a new price target

    Chardan Capital Markets initiated coverage of Lexeo Therapeutics with a rating of Buy and set a new price target of $23.00

    11/28/23 7:28:09 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lexeo Therapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Townsend Richard Nolan was granted 2,193 shares, increasing direct ownership by 1.00% to 222,251 units (SEC Form 4)

    4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

    9/16/25 5:30:06 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: Chief Executive Officer Townsend Richard Nolan sold $5,205 worth of shares (1,115 units at $4.67), decreasing direct ownership by 0.50% to 220,058 units (SEC Form 4)

    4/A - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

    9/10/25 4:59:33 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Tamayo Louis Edward was granted 45,000 shares (SEC Form 4)

    4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

    9/3/25 2:00:05 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Tamayo Louis Edward

    3 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

    8/27/25 6:51:31 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Technical Officer Otero Jose Manuel sold $13,294 worth of shares (2,848 units at $4.67), decreasing direct ownership by 5% to 60,372 units (SEC Form 4)

    4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

    8/20/25 5:05:06 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Legal Officer Robertson Jenny sold $2,530 worth of shares (542 units at $4.67), decreasing direct ownership by 0.86% to 62,556 units (SEC Form 4)

    4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

    8/20/25 5:03:45 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Medical Officer Adler Eric sold $2,838 worth of shares (608 units at $4.67), decreasing direct ownership by 0.90% to 67,073 units (SEC Form 4)

    4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

    8/20/25 5:02:15 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Townsend Richard Nolan sold $12,767 worth of shares (2,735 units at $4.67), decreasing direct ownership by 1% to 220,058 units (SEC Form 4)

    4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

    8/20/25 5:00:18 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Development Officer See Tai Sandi sold $1,783 worth of shares (382 units at $4.67), decreasing direct ownership by 0.64% to 58,860 units (SEC Form 4)

    4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

    8/20/25 4:58:23 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Van Hauwermeiren Timothy

    4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

    6/30/25 5:00:19 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lexeo Therapeutics Inc. Press Releases

    Fastest customizable press release news feed in the world

    View All

    Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034

    Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 8, 2025 /PRNewswire/ -- Ohio State researchers recently solved a critical mystery explaining why some cancer immunotherapies fail[1], while a University of Chicago team discovered a common supplement that supercharges immune cells against tumors[2]. These breakthroughs are propelling the global cancer treatment market from $282 billion in 2025 toward $643.5 billion by 2034[3], creating powerful momentum for companies pioneering next-generation approaches including GT Biopharma, Inc. (NASDAQ:GTBP), Lexeo Therapeutics, Inc. (NASDAQ:LXEO), Anixa Biosciences, Inc. (NASDAQ:ANIX), Tempus AI, Inc. (NASDAQ:TEM)

    10/8/25 10:58:00 AM ET
    $ANIX
    $CTOR
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Computer Software: Programming Data Processing

    Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy

    U.S. Food and Drug Administration (FDA) open to pooling data from ongoing Phase I/II studies of LX2006 with pivotal data to support a Biologics License Application (BLA) for Accelerated Approval Interim clinical data show sustained or deepening improvements in the majority of participants across both cardiac and neurologic measures of Friedreich ataxia Participants with abnormal left ventricular mass index (LVMI) at baseline achieved 18% mean reduction in LVMI at 6 months and 23% mean reduction at 12 months, exceeding FDA-aligned target threshold of 10% reduction Clinically meaningful improvement observed in the modified Friedreich Ataxia Rating Scale (mFARS), indicative of slowed disease

    10/7/25 6:00:00 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights

    Breakthrough Therapy designation granted for LX2006 based on interim data from Phase I/II trials demonstrating clinically meaningful improvements in cardiac and neurologic measures of Friedreich ataxia LX2006 selected for FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot (CDRP) program, created to facilitate CMC registrational readiness and support faster patient access Eight participants dosed in Phase I/II clinical trial (HEROIC-PKP2) of LX2020 for PKP2-ACM; interim clinical data update on track for second half of 2025 Strategic partnership announced with Perceptive Xontogeny Venture Funds and venBio Partners to advance non-viral, RNA-based therapeutics for gene

    8/14/25 7:30:00 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia

    Breakthrough Therapy designation based on interim clinical data from Phase I/II trials showing clinically meaningful improvements in cardiac biomarkers and functional measures LX2006 also selected for FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot (CDRP) program, created to facilitate CMC registrational readiness and support faster patient access NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that the U.S. Food and Drug administration (FDA) has granted Breakthrough Therapy designation to LX2006 ba

    7/7/25 7:00:00 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA Therapeutics

    Up to $40 Million Private Equity Financing into a New Entity Addressing Cardiac Genetic Diseases that Existing AAV Platforms are Unable to Treat Lexeo Contributing Expertise and Know-How in Cardiac Genetic Medicines, Preclinical Intellectual Property, and Technology, in Combination with Novel Non-Viral RNA Delivery Platform Represents Pipeline Diversification and Advancement of Leading-Edge Cardiovascular Science NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced a strategic partnership to develop therapies for genetic cardiac d

    6/24/25 7:30:00 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases

    Cash runway extended into 2028; capital proceeds to fund operations through potential 2027 efficacy readout for LX2006 in Friedreich ataxia cardiomyopathy Financing led by Frazier Life Sciences and Janus Henderson Investors with participation from new and existing investors NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced it has entered into a securities purchase agreement with a select group of institutional and healthcare accredited investors to issue and sell an aggregate of 20,790,120 shares ("Shares") of its common sto

    5/27/25 7:31:10 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights

    Announced positive interim data for LX2006 from Phase 1/2 studies in Friederich ataxia (FA) cardiomyopathy; frataxin expression and LVMI improvement exceeded co-primary target thresholds for planned registrational study LX2006 registrational study expected to begin by early 2026; commencing enrollment in prospective natural history study, CLARITY-FA, in Q2 2025 to serve as concurrent external control Phase 1/2 clinical trial of LX2020 (HEROIC-PKP2) currently enrolling patients in Cohort 3; interim clinical data update on track for second half of 2025 Redeployed $20 million to focus on clinical-stage programs; cash, cash equivalents and investments of $106.9 million expected to prov

    5/12/25 7:00:00 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

    NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, announced today that new data supporting its AAV manufacturing approach will be presented at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) taking place May 13-17, 2025 in New Orleans, LA. "The data being presented at ASGCT underscore the strength of our industry-leading capabilities in AAV manufacturing with high yield and high quality," said José Manuel Otero, Chief Technical Officer of Lexeo Therapeutics. "Scientists at Lexeo have optimized a manufacturing platfo

    5/1/25 9:16:04 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study

    Participants with abnormal left ventricular mass index (LVMI) at baseline achieved 25% mean reduction in LVMI by 12 months or sooner Clinically meaningful improvements in majority of participants across cardiac biomarkers and functional measures All SUNRISE-FA participants achieved meaningful increases in frataxin expression at 3-months post treatment; 115% average cardiac frataxin expression increase in high dose cohort, demonstrating dose response Frataxin expression and LVMI improvement exceed co-primary target thresholds for planned registrational study LX2006 generally well tolerated with no signs of complement activation or other immunogenicity to date Company to host w

    4/7/25 6:00:00 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

    Additional alignment with FDA on LX2006 planned pivotal study including protein expression co-primary endpoint: based on improvements in LVMI across participants with abnormal LVMI at baseline, frataxin expression to be evaluated for any increase from baseline rather than numerical threshold Interim update from cohort 1 of LX2020 HEROIC-PKP2 Phase 1/2 trial: observed 71% and 115% increases in PKP2 protein expression in first two post-treatment biopsies; first participant evaluated 6-months after dosing experienced 67% reduction in premature ventricular contractions (PVCs) Completed enrollment of cohort 2 of LX2020 HEROIC-PKP2 Phase 1/2 trial; interim clinical data update expected in s

    3/24/25 7:00:00 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lexeo Therapeutics Inc. Leadership Updates

    Live Leadership Updates

    View All

    Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer

    NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced that Dr. Kyle Rasbach has been appointed Chief Financial Officer, effective immediately. Dr. Rasbach brings a wealth of life sciences experience to the company and joins ahead of multiple anticipated catalysts across its gene therapy programs. "Kyle has an exceptional track record as an operator and life sciences portfolio manager, and we are excited to welcome him to Lexeo at a time when we are advancing our pipeline and tran

    12/19/24 7:00:00 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results

    Reached alignment with FDA on key elements of registrational development plan for LX2006, including accelerated approval pathway with left-ventricular mass index (LVMI) and frataxin protein expression as co-primary registrational endpoints Received RMAT designation for LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy, potentially enabling expedited development and increased interaction with the FDA Completed enrollment of LX2006 SUNRISE-FA Phase 1/2 trial, with four participants treated in cohort 3; total of 16 participants dosed with LX2006 to date across SUNRISE-FA and Weill Cornell trials Completed enrollment of cohort 1 of LX2020 HEROIC-PKP2 Phase 1/

    11/13/24 7:30:00 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights

    Announced positive interim data from Phase 1/2 studies in Friedreich ataxia (FA) cardiomyopathy, which showed LX2006 was well tolerated with no treatment-related serious adverse events and demonstrated evidence of sustained and consistent treatment effect across multiple cardiac measures Recently initiated formal engagements with FDA on surrogate endpoints for LX2006 registrational study; expects to provide update by end of year Phase 1/2 clinical trial of LX2020 (HEROIC-PKP2) currently recruiting patients; data update from Cohort 1 on track for 2H 2024 Cash and cash equivalents of $175.0 million expected to provide operational runway into 2027 NEW YORK, Aug. 12, 2024 (GLOBE N

    8/12/24 7:00:00 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors

    NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company, today announced the appointment of Tim Van Hauwermeiren, co-founder and Chief Executive Officer of argenx SE, as an independent, non-executive director to its Board of Directors. Mr. Van Hauwermeiren is a seasoned biotech executive with over two decades of experience in both general management and business development across the life sciences and consumer goods industries.   "Tim is a highly accomplished life-sciences entrepreneur who has built one of Europe's most successful biotech companies, and I am thrilled to welcome him to our Board of Directors," said R. N

    7/8/24 7:00:00 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lexeo Therapeutics Inc. Financials

    Live finance-specific insights

    View All

    Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer's Disease, at the Clinical Trials on Alzheimer's Disease (CTAD) Conference

    Dose-dependent increase in neuroprotective APOE2 expression in all participants with ongoing durability at 12 months Consistent reductions across CSF tau biomarkers and tau PET in majority of participants LX1001 well tolerated across all dose cohorts with no reports of amyloid-related imaging abnormalities (ARIA) Company to host webcast today at 7:00 AM ET NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced positive interim results from the Phase 1/2 study of LX1001

    10/30/24 6:14:00 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lexeo Therapeutics Announces Investor Webcast to Report Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy on Monday, July 15, 2024

    NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced that the company will conduct an investor webcast on Monday, July 15, 2024, at 8:00 AM ET to provide an interim clinical data update on LX2006, an AAVrh10.hFXN gene therapy for the treatment of Friedreich ataxia (FA) cardiomyopathy. The presentation will include an overview of the natural history of FA cardiomyopathy and summary of clinically meaningful endpoints, interim data from Lexeo's ongoing SUNRISE-FA Phase 1/2 clinical

    7/11/24 8:00:00 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lexeo Therapeutics Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Lexeo Therapeutics Inc.

    SC 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)

    11/14/24 5:49:30 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Lexeo Therapeutics Inc.

    SC 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)

    11/14/24 4:45:58 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Lexeo Therapeutics Inc.

    SC 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)

    11/14/24 12:32:15 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Lexeo Therapeutics Inc.

    SC 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)

    11/14/24 12:23:07 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Lexeo Therapeutics Inc.

    SC 13G - Lexeo Therapeutics, Inc. (0001907108) (Subject)

    11/12/24 9:31:05 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Lexeo Therapeutics Inc.

    SC 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)

    8/9/24 9:43:21 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Lexeo Therapeutics Inc.

    SC 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)

    8/5/24 12:54:26 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care